www.jtocrr.org/article/S266...

#lcsm #nsclc #zongertinib #tdxd #lungcancer

Zongertinib (Hernexeos) Updates 2025: Uses in Cancer, Side Effects, Dosage, Expectations, and More - OncoDaily Zongertinib is a selective TKI designed to target cancers driven by HER2 mutations. Learn more about its side effects, dosage, expectations.

Zongertinib (Hernexeos) Updates 2025: Uses in Cancer, Side Effects, Dosage, Expectations, and More

oncodaily.com/drugs/zonger...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Zongertinib #Hernexeos #LungCancer #NSCLC

FDA Grants Accelerated Approval to Zongertinib in HER2 NSCLC Zongertinib gains FDA approval for advanced NSCLC with HER2 mutations, showcasing promising efficacy and safety in clinical trials.

The FDA has granted accelerated approval to #zongertinib in HER2+ #NSCLC. Read about the breaking regulatory decision here → www.targetedonc.com/view/fda-gra...

Boehringer Ingelheim Presents Innovative Cancer Treatments at ASCO 2025 At ASCO 2025, Boehringer Ingelheim showcases their cutting-edge cancer therapies, emphasizing breakthroughs in HER2-mutant NSCLC and neuroendocrine carcinomas.

Boehringer Ingelheim Presents Innovative Cancer Treatments at ASCO 2025 #United_States #Chicago #Boehringer_Ingelheim #Zongertinib #Obrixtamig

The phase 1b #Zongertinib trial delivers promising results for patients with previously treated HER2-mutant #NSCLC

@nejm.org

#Onco404 #Cancer #Kanser #MedSky #OncSky #LungCancer #AkciğerKanseri #HER2 #TargetedTherapy #ClinicalTrials

Selective HER2 inhibitor promising in previously treated HER2-mutant NSCLC Phase 1b trial data point to the potential of zongertinib, a novel HER2 inhibitor, for previously treated patients with HER2-mutant non-small-cell lung cancer.

#MedNews - Phase 1b trial data point to the potential of #zongertinib, a novel #HER2 inhibitor, for previously treated patients with HER2-mutant non-small-cell #LungCancer.

Full story 👉 buff.ly/rZPTjFk

#OncSky #NSCLC

#Zongertinib, a pill with activity against some HER2-mutant cancers? Yup. @nejm.org www.nejm.org/doi/full/10.... #AACR25 www.fiercebiotech.com/biotech/aacr...

Boehringer Ingelheim's Zongertinib Shows Promising Results in HER2-Mutant Lung Cancer Boehringer Ingelheim's latest data reveals zongertinib's effectiveness in treating advanced NSCLC with HER2 mutations, indicating a significant breakthrough.

Boehringer Ingelheim's Zongertinib Shows Promising Results in HER2-Mutant Lung Cancer #Germany #Ingelheim #Zongertinib #Non-Small_Cell_Lung_Cancer #HER2-mutant

Boehringer's Zongertinib Receives FDA Priority Review for Lung Cancer Treatment Boehringer's zongertinib gains Priority Review from the FDA, marking a potential breakthrough in treating HER2-mutant advanced lung cancer.

Boehringer's Zongertinib Receives FDA Priority Review for Lung Cancer Treatment #USA #Boehringer_Ingelheim #HER2_Mutations #Zongertinib #Ridgefield,_Connecticut

📊 Erste Real-World-Daten zu Zongertinib bei HER2+ NSCLC: Klin. & radiolog. Benefit bei allen Patient:innen inkl. kompletter Remission von Hirnmetastasen, Gute Verträglichkeit. Mehr erfahren? s. Kommentar.
#lcsm #oncology #her2 #zongertinib #targetedtherapy @oliverillini.bsky.social

Redirecting

We just published our first real-world experience with #zongertinib in HER2+Lungcancer
@lungenforschung.bsky.social. ✅Benefit in pretreated pat ✅Safe 🧠CR. #LCSM
@oncoalert.bsky.social @exon20group.bsky.social @lungcancerresearch.bsky.social
OA-@elsevierconnect.bsky.social
doi.org/10.1016/j.ct...